MX2023005171A - Composiciones y metodos para tratamiento de cancer solido. - Google Patents
Composiciones y metodos para tratamiento de cancer solido.Info
- Publication number
- MX2023005171A MX2023005171A MX2023005171A MX2023005171A MX2023005171A MX 2023005171 A MX2023005171 A MX 2023005171A MX 2023005171 A MX2023005171 A MX 2023005171A MX 2023005171 A MX2023005171 A MX 2023005171A MX 2023005171 A MX2023005171 A MX 2023005171A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- solid cancer
- treating solid
- treating
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/0101—Chloride peroxidase (1.11.1.10)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/02—Oxidoreductases acting on a peroxide as acceptor (1.11) with H2O2 as acceptor, one oxygen atom of which is incorporated into the product (1.11.2)
- C12Y111/02002—Myeloperoxidase (1.11.2.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063112447P | 2020-11-11 | 2020-11-11 | |
| PCT/US2021/053155 WO2022103515A1 (en) | 2020-11-11 | 2021-10-01 | Compositions and methods for treating solid cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005171A true MX2023005171A (es) | 2023-06-26 |
Family
ID=81601629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005171A MX2023005171A (es) | 2020-11-11 | 2021-10-01 | Composiciones y metodos para tratamiento de cancer solido. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230398190A1 (https=) |
| EP (1) | EP4243835A4 (https=) |
| JP (1) | JP2023548406A (https=) |
| KR (1) | KR20230106646A (https=) |
| CN (1) | CN116710121A (https=) |
| AU (1) | AU2021379542A1 (https=) |
| CA (1) | CA3196357A1 (https=) |
| IL (1) | IL302683A (https=) |
| MX (1) | MX2023005171A (https=) |
| WO (1) | WO2022103515A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250332226A1 (en) * | 2022-04-13 | 2025-10-30 | Exoxemis, Inc. | Compositions and methods for treating solid cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4486408A (en) * | 1981-04-07 | 1984-12-04 | Kiel Johnathan L | Insoluble crosslinked cytotoxic oxidase-peroxidase system |
| WO2007103525A2 (en) * | 2006-03-09 | 2007-09-13 | Glanbia Nutritionals (Ireland) Limited | Cationic whey protein composition |
| WO2013009910A2 (en) * | 2011-07-11 | 2013-01-17 | Exoxemis, Inc. | Eosinophil peroxidase compositions and methods of their use |
| EP4548978A3 (en) * | 2015-01-29 | 2025-08-06 | Oxyrase, Inc. | Methods for inhibiting tumor growth |
| US10213448B2 (en) * | 2016-03-25 | 2019-02-26 | Novazoi Theranostics | Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof |
| US20190271703A1 (en) * | 2016-10-26 | 2019-09-05 | Duke University | Biomarkers and treatments for metastatic cancer |
-
2021
- 2021-10-01 CA CA3196357A patent/CA3196357A1/en active Pending
- 2021-10-01 EP EP21892530.3A patent/EP4243835A4/en active Pending
- 2021-10-01 WO PCT/US2021/053155 patent/WO2022103515A1/en not_active Ceased
- 2021-10-01 JP JP2023527693A patent/JP2023548406A/ja active Pending
- 2021-10-01 KR KR1020237019076A patent/KR20230106646A/ko active Pending
- 2021-10-01 CN CN202180076110.4A patent/CN116710121A/zh active Pending
- 2021-10-01 IL IL302683A patent/IL302683A/en unknown
- 2021-10-01 MX MX2023005171A patent/MX2023005171A/es unknown
- 2021-10-01 AU AU2021379542A patent/AU2021379542A1/en active Pending
- 2021-10-01 US US18/035,480 patent/US20230398190A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230398190A1 (en) | 2023-12-14 |
| WO2022103515A1 (en) | 2022-05-19 |
| KR20230106646A (ko) | 2023-07-13 |
| CA3196357A1 (en) | 2022-05-19 |
| EP4243835A1 (en) | 2023-09-20 |
| AU2021379542A1 (en) | 2023-06-08 |
| JP2023548406A (ja) | 2023-11-16 |
| IL302683A (en) | 2023-07-01 |
| AU2021379542A9 (en) | 2024-09-05 |
| EP4243835A4 (en) | 2024-08-28 |
| CN116710121A (zh) | 2023-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| MX2023012245A (es) | Compuestos, composiciones y metodos para el tratamiento del cancer. | |
| JOP20180039A1 (ar) | مثبطات pd-1/pd-l1 | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| MX2024005228A (es) | Inhibidores de la sustitución de glicina a cisteína en la posición 12 (g12c) en el homólogo del oncogén viral de sarcoma de rata kirsten (kras). | |
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| MX392368B (es) | Composiciones y metodos para el tratamiento del cancer | |
| MX2019012038A (es) | Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico. | |
| NZ742787A (en) | Compositions comprising bacterial strains | |
| NZ746554A (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | |
| MX2019001517A (es) | Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer. | |
| MX2019008158A (es) | Terapia de combinacion para el tratamiento del cancer. | |
| CR20240296A (es) | Inhibidores parp1 | |
| WO2020055643A3 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| MX2024014238A (es) | Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer | |
| MX2022008099A (es) | Tratamiento para el cancer con inhibidores de cdk12/13. | |
| MX2024014830A (es) | Compuestos de degradacion de wee1 y usos de los mismos | |
| WO2021038296A3 (en) | Modified tff2 polypeptides | |
| MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. | |
| MX2025000552A (es) | Conjugados anticuerpo-fármaco | |
| PH12022551371A1 (en) | Macrocycles for use in treating disease | |
| MX2023006087A (es) | Formulaciones liofilizadas de tegavivint. | |
| MY200161A (en) | Bacteria for targeting tumors and treating cancer | |
| WO2020033019A3 (en) | Novel mct4 inhibitors and uses thereof | |
| WO2022036065A3 (en) | Compositions and methods for treating cancers |